

Treating rheumatoid arthritis with hydroxychloroquine (HCQ) may reduce the risk of nonalcoholic fatty liver disease (NAFLD), particularly in younger men and women, according to a study presented at ACR Convergence 2023. The study analyzed data from over 21,000 patients in Taiwan and found that HCQ was associated with a significantly lower risk of NAFLD, potentially due to its effect on adiponectin levels. However, further research is needed to confirm these findings.


Treating rheumatoid arthritis with hydroxychloroquine (HCQ) may reduce the risk of nonalcoholic fatty liver disease (NAFLD), particularly in younger men and women, according to a study presented at ACR Convergence 2023. The study analyzed data from over 21,000 patients in Taiwan and found that HCQ was associated with a significantly lower risk of NAFLD, potentially due to its effect on adiponectin levels. However, further research is needed to confirm these findings.
•The study analyzed data from over 21,000 patients in Taiwan.
•HCQ was associated with a significantly lower risk of NAFLD, especially in younger patients.
•The effect may be due to HCQ's impact on adiponectin levels.
•Further research is needed to confirm these findings.







